PSC
NBIX icon

Portman Square Capital’s Neurocrine Biosciences NBIX Stock Holding History

Portman Square Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-95,600
Closed -$13.2M – 359
2024
Q1 		$13.2M Hold
95,600
– – 0.37% 81
2023
Q4 		$12.6M Buy
+95,600
New +$11M 0.29% 87

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Portman Square Capital's NBIX Position: Q3 2024 in Review

Portman Square Capital sold out of Neurocrine Biosciences (NBIX) in Q3 2024, closing a stake of 10,457 shares — an estimated $1.44M sold.

Portman Square Capital first reported a position in NBIX in Q4 2023 and held it in 3 quarters. The position peaked at $1.44M in Q2 2024. 574 funds tracked by Wall St. Rank hold NBIX as of Q3 2024.

  • Portman Square Capital reported no remaining Neurocrine Biosciences position as of Q3 2024 after selling out during the quarter.
  • Portman Square Capital sold 10,457 Neurocrine Biosciences shares in Q3 2024, an estimated $1.44M.
  • Portman Square Capital first reported a position in Neurocrine Biosciences in Q4 2023 and held it in 3 quarters.
  • Portman Square Capital's Neurocrine Biosciences position peaked at $1.44M in Q2 2024.
  • 574 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2024.

Based on Portman Square Capital's 13F filing for Q3 2024, filed 16 Oct 2024.